Filter by tags: Radiopharmaceutical Germany Clear all tag filters
3 news articles found
Nuclear operator Bruce Power aiming to increase production of lutetium-177
- Source: Nucnet
- Date: Saturday, 01 July 2023
- Original article: nucnet.org/news/government-invests-cad-35-million-for-development-of-crucial-radioisotopes-6-5-2023
Canadian Nuclear Laboratories (CNL) is to collaborate with US-based Jubilant Radiopharma to develop alpha radiopharmaceuticals. The joint project comes under CNL’s Canadian Nuclear Research Initiative -Health (CNRI-H) programme. It is part of a broader CNL effort to develop radiopharmaceutical therapies using Actinium-225, a medical isotope produced by CNL.
- Source: NEI Magazine
- Date: Wednesday, 08 February 2023
- Original article: neimagazine.com/news/newscnl-and-jubilant-radiopharma-collaborate-on-actinium-225-10574940
Lutetium-177 (Lu-177) has been produced using a new isotope production system (IPS) that was installed in unit 7 of the Bruce plant in Ontario, Canada, during a recent planned maintenance outage. It marks the first time the short-lived medical isotope has been produced in a commercial nuclear power reactor.
- Source: World Nuclear News
- Date: Thursday, 23 June 2022
- Original article: world-nuclear-news.org/Articles/Canadian-Candu-produces-cancer-therapy-isotope